>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

SB-431542

SB-431542 是一种有效，选择性的 ALK5/TGF-β type I Receptor 抑制剂，IC50 值为 94 nM。

货号：
TK0170
规格：

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	301836-41-9
生物活性	SB-431542 is a potent and selective inhibitor of ALK5/TGF-β type I Receptor with an IC50 value of 94 nM.
分子式	C22H16N4O3
分子量	384.39
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : 250 mg/mL (650.38 mM; Need ultrasonic) Ethanol : 11.17 mg/mL (29.06 mM; Need ultrasonic and warming)
体内研究	SB-431542 (10 mg/kg, i.p.) decreases lung metastasis but does not significantly alter growth of the primary tumor 4T1 xenograft.
体外研究	SB-431542 (1 μM) significantly reduces the TGF-β-induced nuclear accumulation of Smad proteins in A498 cells. SB-431542 inhibits TGF-β1-induced collagen Iα1 and PAI-1 mRNA with IC50 values of 60 and 50 nM, respectively. In addition, SB-431542 inhibits TGF-β1-induced fibronectin mRNA and protein with IC50 values of 62 and 22 nM, respectively. SB-431542 (10 μM) is a selective inhibitor of TGF-β signaling but has no effect on BMP signaling in NIH 3T3 cells. TRKI, SB-431542, inhibits TGF-beta-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 attenuates the tumor-promoting effects of TGF-beta, including TGF-beta-induced EMT, cell motility, migration and invasion, and vascular endothelial growth factor secretion in human cancer cell lines. SB-431542 induces anchorage independent growth of cells that are growth-inhibited by TGF-beta, whereas it reduces colony formation by cells that are growth-promoted by TGF-beta. SB-431542 (0.3 μM) inhibits cell proliferation induced by TGF-β in MG63 cells.
文献	•Gut. 2022 Jan 7;gutjnl-2021-325018. •Small. 2020 Jun;16(22):e2001371. •Cancer Res. 2020 Oct 15;80(20):4426-4438. •Cancer Res. 2019 Sep 1;79(17):4466-4479. •Biomaterials. 2020 May;240:119849. •EMBO Mol Med. 2020 Jan 9;12(1):e10681. •Theranostics. 2021 May 13;11(14):7110-7125. •Theranostics. 2021 Mar 4;11(9):4483-4501. •Oncogene. 2020 May;39(22):4450-4464. •Cell Rep. 2020 Apr. •Br J Pharmacol. 2021 Mar;178(5):1037-1054. •Exp Mol Med. 2021 Sep 21. •Cell Death Dis. 2021 Dec 20;13(1):16. •Neurotherapeutics. 2020 Apr;17(2):690-703. •J Med Chem. 2019 Sep 12;62(17):7961-7975. •Stem Cell Res Ther. 2021 Dec 20;12(1):608. •Stem Cell Res Ther. 2021 Jun 10;12(1):338. •Stem Cell Res Ther. 2021 Jun 11;12(1):345. •Stem Cell Res Ther. 2020 Jun 3;11(1):210. •Stem Cell Res Ther. 2020 Apr 29;11(1):166. •Cell Prolif. 2019 Jul;52(4):e12637. •Front Cell Dev Biol. 2021 Jun 18;9:659389. •Front Cell Dev Biol. 2021 May 31;9:667252. •Mol Oncol. 2018 Mar;12(3):305-321. •Biomed Pharmacother. 2020 May;125:109768. •Biomed Pharmacother. 2020 Feb;122:109388. •Biomed Pharmacother. 2020 Mar;123:109807. •J Cell Physiol. 2020 Mar;235(3):2655-2667. •J Cell Physiol. 2020 Apr;235(4):3558-3568. •Stem Cells. 2019 Feb;37(2):190-201. •Clin Sci. 2019 Oct 30;133(20):2069-2084. •Biomedicines. 2021 Nov 15;9(11):1692. •Int J Mol Sci. 2018 May 23;19(6). pii: E1556. •Int J Mol Sci. 2017 Apr 18;18(4). pii: E853. •Phytother Res. 2019 Jan;33(1):214-223. •Front Pharmacol. 2021 Mar 25;12:644638. •Aging. 2020 Oct 25;12(20):20047-20068. •FEBS J. 2020 Feb;287(4):783-799. •J Transl Med. 2021 Dec 7;19(1):497. •J Cell Mol Med. 2020 May;24(9):5195-5204. •J Cell Mol Med. 2018 Sep;22(9):4354-4365. •Bioorg Chem. 2021, 105222. •FASEB J. 2020 Oct;34(10):13461-13473. •J Biol Chem. 2021 Oct 13;101303. •J Biol Chem. 2019 Oct 25;294(43):15808-15825. •Int Immunopharmacol. 2015 Sep;28(1):707-14. •Mol Carcinog. 2020 Jun;59(6):651-660. •Toxins. 2021 Aug 22;13(8):585. •Molecules. 2019 Jan 2;24(1):144. •Sci Rep. 2020 Jan 28;10(1):1281. •Sci Rep. 2019 Mar 5;9(1):3462. •J Ethnopharmacol. 2021 Jan 29;113893. •J Ethnopharmacol. 2020 Mar 1;249:112404. •Onco Targets Ther. 2018 Nov 21;11:8251-8263. •Mol Cell Endocrinol. 2021 Jan 1;519:111055. •Int J Mol Med. 2018 Dec;42(6):3395-3403. •Brain Res Bull. 2018 May;139:38-47. •Cancer Manag Res. 2021 May 7;13:3685-3697. •J Tissue Eng Regen Med. 2021 Aug 7. •J Mater Sci Mater Med. 2020 Nov 30;31(12):130. •Am J Reprod Immunol. 2021 Mar;85(3):e13344. •Skelet Muscle. 2020 May 2;10(1):13. •Immunol Lett. 2019 Feb;206:33-40. •Exp Eye Res. 2019 Mar 23;182:44-56. •Mol Cell Biochem. 2018 Feb;439(1-2):117-129. •Dig Dis Sci. 2021 Nov 19. •Oncol Lett. 2018 Jun;15(6):9681-9686. •Oncol Lett. 2018 Mar;15(3):2801-2806. •Oncol Lett. 2017 Jul;14(1):541-546. •Mol Med Rep. 2019 Mar;19(3):2107-2114. •Animals. 2021 Feb 6;11(2):425. •Steroids. 2021, 108887. •J Mol Histol. 2021 Feb;52(1):77-86. •Acta Histochem. 2015 Jul;117(6):551-558. •Exp Ther Med. 2021 Feb 25. •Authorea. January 12, 2022. •Research Square Preprint. 2021 Sep. •Research Square Preprint. 2021 May. •Research Square Preprint. 2021 Apr. •bioRxiv. 2021 Feb 25. •Cell Rep Med. 2020 Dec 22;1(9):100161. •Research Square Preprint. 2020 Aug. •Brain Hemorrhages. 2020 Jul. •School of Medical Sciences. University of Sydney. 2018 Jul. •Chin J Immun. 2016 (5): 615-619.
纯度及产品资料	98%

推荐产品